A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · FACTORIAL · PREVENTION · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 2157
- Population
- ALL · 70 Years
- Duration
- 2012-12-20 to 2018-01-19
- Intervention
- Vitamin D3; Omega 3 fatty acids; Strength Home Exercise; Flexibility Home Exercise
- Comparator
- VitD-Omega3-StrengthExercise; VitD-Omega3-FlexibilityExercise; Placebo-Omega3-StrengthExercise; Placebo-Omega3-FlexibilityExercise; VitD-Placebo-StrengthExercise; VitD-Placebo-FlexiblityExercise; Placebo-Placebo-StrengthExercise
- Outcomes measured
- Bone: Incident non-vertebral fractures over 36 months — over 36 months; Muscle: Functional decline (lower extremity function) — Baseline, 12, 24 and 36 months; Cardio-vascular: Systolic and diastolic blood pressure change — Baseline, 12, 24 and 36 months; Brain: Cognitive decline — Baseline, 12, 24 and 36 months; Immunity: Rate of any infections — Baseline, and every 3 months up to 36 months; Bone: Incident hip fractures — 36 months; Bone: Incident total fractures — 36 months; Bone: Incident vertebral fractures — 36 months; Bone: Bone mineral density decrease at the lumbar spine and hip — Baseline, 12, 24, and 36 months; Muscle: Rate of falls — Assessed every 3 months over 36 months; Muscle: reaction time and grip strength — Baseline, 12,24,36 months; Muscle: Muscle mass decrease at upper and lower extremities — Baseline, 12,24,36 months; Muscle: Dual tasking 10-meter gait speed — Baseline, 12,24 and 36 months; Muscle/Bone: musculoskeletal pain — Baseline, 12,24, and 36 months; Cardio-vascular: Incident Hypertension — 36 months; Brain: mental health decline — Baseline, 12,24, and 36 months; Brain: Incident Depression — 36 months; Brain/Muscle: Dual tasking gait variability — Baseline, 12, 24 and 36 months; Immunity: Rate of upper respiratory infections / rate of flu-like illness — 36 months; Immunity: Incident severe infections that lead to hospital admission — 36 months
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Exercise · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
- Vitamin D and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.